Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAD induction therapy in previously untreated multiple myeloma
ACTRN12609000296235Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, doxorubicin and dexamethasone in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall response rate after 4 cycles of PAD by baseline 1q21 amplification status. Started Jan 2009; status: completed.
02
Drugs
bortezomibdoxorubicindexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12609000296235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000296235.